Last reviewed · How we verify

dalfampridine ER

Brown, Theodore R., M.D., MPH · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

dalfampridine ER is a Small molecule drug developed by Brown, Theodore R., M.D., MPH. It is currently FDA-approved. Also known as: Ampyra serial number 77948545.

Dalfampridine ER is a small molecule medication used to treat conditions such as post-ischemic stroke and multiple sclerosis, as indicated by ClinicalTrials.gov. It is available in two dose strengths, 7.5mg and 10mg, and is administered orally in extended release tablet form.

At a glance

Generic namedalfampridine ER
Also known asAmpyra serial number 77948545
SponsorBrown, Theodore R., M.D., MPH
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dalfampridine ER

What is dalfampridine ER?

dalfampridine ER is a Small molecule drug developed by Brown, Theodore R., M.D., MPH.

Who makes dalfampridine ER?

dalfampridine ER is developed and marketed by Brown, Theodore R., M.D., MPH (see full Brown, Theodore R., M.D., MPH pipeline at /company/brown-theodore-r-m-d-mph).

Is dalfampridine ER also known as anything else?

dalfampridine ER is also known as Ampyra serial number 77948545.

What development phase is dalfampridine ER in?

dalfampridine ER is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing